N-desmethyltoremifene: metabolite of toremifene; structure given in first source; RN given refers to (Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3035212 |
| CHEBI ID | 169918 |
| SCHEMBL ID | 5725379 |
| MeSH ID | M0172403 |
| Synonym |
|---|
| 110503-61-2 |
| 2-[4-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n-methylethanamine |
| CHEBI:169918 |
| n-desmethyltoremifene |
| 2ebs4a61gk , |
| unii-2ebs4a61gk |
| n-demethyltoremifene |
| ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n-methyl-, (z)- |
| 2-(4-((1z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-n-methylethanamine |
| SCHEMBL5725379 |
| tore i |
| (z)-4-chloro-1,2-diphenyl-1-(4-(2-(n-methylamino)ethoxy)phenyl)-1-butene |
| fc-1200 |
| ethanamine, 2-(4-((1z)-4-chloro-1,2-diphenyl-1-buten-1-yl)phenoxy)-n-methyl- |
| J-002434 |
| n-desmethyl toremifene hydrochloride salt |
| n-desmethyltoremifene hydrochloride |
| Q27254624 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "A multicenter phase I pharmacokinetic study of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer." | ( Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Benz, CC; Cadman, TB; DeGregorio, MW; Shemano, I; Wiebe, VJ, 1990) | 0.28 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Due to the potential for drug-drug interactions, the ability of toremifene and its primary circulating metabolite N-desmethyltoremifene (NDMT) to inhibit nine human cytochrome P450 (CYP) enzymes was determined using human liver microsomes." | ( Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Dalton, JT; Johanning, KM; Kim, J; Peraire, C; Solà, J; Veverka, KA, 2011) | 0.84 |
| Class | Description |
|---|---|
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||